Table 1.
Patients characteristics.
| Characteristics | RRMS Rel (n = 43) | RRMS Rem (n = 21) | HD (n = 20) | CD (n =16) |
|---|---|---|---|---|
| Median age, years (IQR, range) |
35 (14; 22–53) |
40 (14.5; 25–52) |
29.5 (17.5; 25–61) |
28.5 (21.3; 18–69) |
| Gender Women n, (%) Men n, (%) |
38 (88.4%) 5 (11.6%) |
19 (90.5%) 2 (9.5%) |
16 (80%) 4 (20%) |
7 (43.8%) 9 (56.2%) |
| Months from diagnosisto sample collection, median (IQR, range) |
9 (144; 0–36) |
12 (70.5; 0–216) |
192 (231; 1–456) |
|
| Type of MS/CIS MS n, (%) CIS n, (%) |
33 (76.7%) 10 (23.3%) |
13 (61.9%) 8 (38.1%) |
||
| Naïve Yes n, (%) No n, (%) |
24 (55.8%) 19 (44.2%) |
16 (76.2%) 5 (23.8%) |
0 16 (100%) |
|
| Type of treatment in non-naïve (n) | ||||
| Interferon beta-1a sc | 4 | 2 | ||
| Glatitamer Acetate | 5 | 1 | ||
| Interferon beta-1b | 2 | 1 | ||
| Azathioprine | 1 | 1 | ||
| Interferon beta-1b im | 5 | |||
| Methylprednisolone | 1 | |||
| Dimethyl fumarate | 1 | 1 | ||
| Adalimumab | 5 | |||
| Adalimumab + azathioprine | 2 | |||
| Infliximab | 1 | |||
| Vedolizumab | 4 | |||
| Certolizumab + Methylprednisolone | 1 | |||
| Azathioprine + Prednisone | 1 | |||
| Prednisone | 1 |
RRMS, remitting-recurrent multiple sclerosis; rel, relapsing; rem, remitting; HD, healthy donor; CD, Crohn’s disease; MS, multiple sclerosis; CIS, clinically isolated syndrome; mAb, monoclonal antibody; sc, subcutaneous; im, intramuscular.